Quantitative assessment of gene methylation and their impact on clinical outcome in gastric cancer

Clinica Chimica Acta

Volumn 413, Issue 7-8, 2012, Pages 787-794

  Yao, Demao ^a   Shi, Jing ^a   Shi, Bingyin ^a   Wang, Na ^a   Liu, Wei ^a   Zhang, Guanjun ^a   Ji, Meiju ^a   Xu, Li ^a   He, Nongyue ^b   Hou, Peng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

Author keywords

Early diagnosis; Gastric cancer; Gene methylation; Poor survival; Quantitative methylation specific PCR (Q MSP)

Indexed keywords

ADULT; ARTICLE; CALCA GENE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DAPK1 GENE; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METHYLATION; ONCOGENE; PAX6 GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE METHYLATION SPECIFIC PCR; RARBETA GENE; RASSF1A GENE; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; TIMP3 GENE; TUMOR DIFFERENTIATION;

AGED; BASE SEQUENCE; DNA METHYLATION; DNA PRIMERS; FEMALE; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84862832734     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.01.013     Document Type: Article

References (39)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Kim H.J., Karpeh M.S. Surgical approaches and outcomes in the treatment of gastric cancer. Semin Radiat Oncol 2002, 12:162-169.
3. Allgayer H., Heiss M.M., Schildberg F.W. Prognostic factors in gastric cancer. Br J Surg 1997, 84:1651-1664.
4. Yasui W., Oue N., Kuniyasu H., Ito R., Tahara E., Yokozaki H. Molecular diagnosis of gastric cancer: present and future. Gastric Cancer 2001, 4:113-121.
5. Yokozaki H., Yasui W., Tahara E. Genetic and epigenetic changes in stomach cancer. Int Rev Cytol 2001, 204:49-95.
6. Yasui W., Oue N., Aung P.P., Matsumura S., Shutoh M., Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 2005, 8:86-94.
7. Feinberg A.P. Cancer epigenetics takes center stage. Proc Natl Acad Sci U S A 2001, 98:392-394.
8. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3:415-428.
9. Resende C., Ristimäki A., Machado J.C. Genetic and epigenetic alteration in gastric carcinogenesis. Helicobacter 2010, 15(Suppl. 1):34-39.
10. Toyota M., Ahuja N., Suzuki H., et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999, 59:5438-5442.
11. Leung W.K., Yu J., Ng E.K., et al. Concurrent hypermethylation of multiple tumor-related genes in gastric carcinoma and adjacent normal tissues. Cancer 2001, 91:2294-2301.
12. Oue N., Oshimo Y., Nakayama H., et al. DNA methylation of multiple genes in gastric carcinoma: association with histological type and CpG island methylator phenotype. Cancer Sci 2003, 94:901-905.
13. El Hage F., Stroobant V., Vergnon I., et al. Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway. Proc Natl Acad Sci U S A 2008, 105:10119-10124.
14. Martoriati A., Doumont G., Alcalay M., Bellefroid E., Pelicci P.G., Marine J.C. dapk1, encoding an activator of a p19ARF-p53-mediated apoptotic checkpoint, is a transcription target of p53. Oncogene 2005, 24:1461-1466.
15. Alvarez S., Germain P., Alvarez R., Rodríguez-Barrios F., Gronemeyer H., de Lera A.R. Structure, function and modulation of retinoic acid receptor beta, a tumor suppressor. Int J Biochem Cell Biol 2007, 39:1406-1415.
16. Mahller Y.Y., Vaikunth S.S., Ripberger M.C., et al. Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res 2008, 68:1170-1179.
17. Robson E.J., He S.J., Eccles M.R. A PANorama of PAX genes in cancer and development. Nat Rev Cancer 2006, 6:52-62.
18. Donninger H., Vos M.D., Clark G.J. The RASSF1A tumor suppressor. J Cell Sci 2007, 120:3163-3172.
19. Hou P., Liu D., Shan Y., et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 2007, 13:1161-1170.
20. Hou P., Ji M., Xing M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 2008, 113:2440-2447.
21. Ji M., Guan H., Shi B., Hou P. Concomitant hypermethylation of multiple genes in non-small cell lung cancer (NSCLC). Folia Histochem Cytobiol 2011, 49:132-141.
22. Hu S., Liu D., Tufano R.P., et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer 2006, 119:2322-2329.
23. Kang G.H., Lee S., Kim J.S., Jung H.Y. Profile of aberrant CpG island methylation along multistep gastric carcinogenesis. Lab Invest 2003, 83:519-526.
24. Vogiatzi P., Vindigni C., Roviello F., Renieri A., Giordano A. Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis. J Cell Physiol 2007, 211:287-295.
25. Paixao V.A., Vidal D.O., Caballero O.L., et al. Hypermethylation of CpG island in the promoter region of CALCA in acute lymphoblastic leukemia with central nervous system (CNS) infiltration correlates with poorer prognosis. Leuk Res 2006, 30:891-894.
26. Brait M., Begum S., Carvalho A.L., et al. Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev 2008, 17:2786-2794.
27. Loyo M., Brait M., Kim M.S., et al. A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. Int J Cancer 2011, 128:1393-1403.
28. Ji M., Guan H., Gao C., Shi B., Hou P. Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer 2011, 11:147.
29. Martinez-Glez V., Franco-Hernandez C., Gonzalez-Gomez P., et al. DAPK1 promoter hypermethylaiton in brain metastases and peripheral blood. Neoplasma 2007, 54:123-126.
30. Ben Ayed-Guerfali D., Benhaj K., Khabir A., et al. Hypermethylation of tumor-related genes in Tunisian patients with gastric carcinoma: clinical and biological significance. J Surg Oncol 2011, 103:687-694.
31. Hayashi K., Yokozaki H., Goodison S., et al. Inactivation of retinoic acid receptor beta by promoter CpG hypermethylation in gastric cancer. Differentiation 2001, 68:13-21.
32. Ikoma H., Ichikawa D., Koike H., et al. Correlation between serum DNA methylation and prognosis in gastric cancer patients. Anticancer Res 2006, 26:2313-2316.
33. Ye M., Xia B., Guo Q., Zhou F., Zhang X. Association of diminished expression of RASSF1A with promoter methylation in primary gastric cancer from patients of central China. BMC Cancer 2007, 7:120.
34. Guo W., Dong Z., Chen Z., et al. Aberrant CpG island hypermethylation of RASSF1A in gastric cardia adenocarcinoma. Cancer Invest 2009, 27:459-465.
35. Gu P., Xing X., Tänzer M., et al. Frequent loss of TIMP-3 expression in progression of esophageal and gastric adenocarcinomas. Neoplasia 2008, 10:563-572.
36. Hellwinkel O.J., Kedia M., Isbarn H., Budäus L., Friedrich M.G. Methylation of the TPEF- and PAX6-promoters is increased in early bladder cancer and in normal mucosa adjacent to pTa tumours. BJU Int 2008, 101:753-757.
37. Moelans C.B., Verschuur-Maes A.H., van Diest P.J. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. J Pathol 2011, 225:222-231.
38. Ksiaa F., Ziadi S., Amara K., Korbi S., Trimeche M. Biological significance of promoter hypermethylation of tumor-related genes in patients with gastric carcinoma. Clin Chim Acta 2009, 404:128-133.
39. Sugita H., Iida S., Inokuchi M., et al. Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer. Oncol Rep 2011, 25:513-518.